You are here
Dr Trevelyan Menheniott
Dr Trevelyan Menheniott is a molecular biologist with 15 years experience in cancer epigenetics and immunology research. He obtained his PhD in mammalian epigenetics from the University of Bath, UK in 2004. His postdoctoral work was completed in the laboratory of Professor Rebecca Oakey, King's College London, then subsequently with Professor Andrew Giraud at the University of Melbourne. He relocated with the group to the Murdoch Childrens Research Institute in 2007.
Dr Menheniott has achieved significant National Health and Medical Research Council (NHMRC) funding success as Chief Investigator since joining the Murdoch Childrens Research Institute, with six grants awarded since 2009 worth $3.1 million and a recent NHMRC Career Development Fellowship which commenced in 2012. Dr Menheniott was appointed as Group Leader in 2012 and currently co-leads the Gastrointestinal Research in Inflammation & Pathology (GRIP) team with Professor Giraud and Dr Louise Judd.
- NHMRC Career Development Fellowship (2012-15)
- Career grant funding (since 2009) of six awards totalling $3 million
- Honorary Research Fellow appointment, Department of Paediatrics, University of Melbourne (2013-present)
- Speaker prize winner, United European Gastroenterology Week, Berlin, Germany (2013)
- Quayle prize, awarded for excellence in Ph.D. research), University of Bath, UK (2003)
Dr Trevelyan Menheniott's research aims to highlight how aberrant epigenetic signatures are triggered by chronic gastrointestinal inflammation and to further understand how these forms of immune-related 'epigenetic memory' influence epithelial differentiation, renewal and cancer development. A specific priority of his research involves translation of these 'immune-epigenetic signatures' into 'cell-free DNA' biomarkers as a strategy to improve the early detection of gastrointestinal cancers. A secondary goal aims to understand how a family of novel immunomodulatory proteins, known as 'gastrokines', suppress gastrointestinal inflammation and how their loss of function may accelerate the progression of inflammatory disease and cancer. His team is currently using a range of mouse genetic and bacterial infection models, human clinical cohorts, in vitro systems and advanced molecular techniques to address questions central to the above research aims.
- Functional analysis of gastrokine proteins and their roles in mucosal immunity and disease
- Development of cell-free DNA biomarkers for early detection of gastric cancer
- Roles of inflammation-related 'epigenetic memory' in gastrointestinal disease
- Human gene loss events in the evolution of host-microbe interactions
Kurklu B, Whitehead RH, Ong EK, Minamoto T, Fox JG, Mann JR, Judd LM, Giraud AS*, Menheniott TR*. Lineage-specific RUNX3 hypomethylation marks the preneoplastic immune component of gastric cancer. Oncogene. 2014. In press (PMID: 25088199) *joint senior authors
Däbritz J and Menheniott TR. Linking immunity, epigenetics and cancer in IBD. Inflammatory Bowel Diseases. 2014. In press (PMID:24896241)
Menheniott TR*, Judd LM*, Ling H, Jackson CB, Howlett M, Kalantzis A, Priebe W, Giraud AS. Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo. PLoS ONE. 2014; 9(5): e95993 *Equal first authors
Menheniott TR, Kurklu B, Giraud AS. Gastrokines: stomach-specific proteins with putative homeostatic and tumor suppressor roles. Am J Physiol Gastrointest Liver Physiol. 2013; 304: G109-21
Lee KS, Kalantzis A, Jackson CB, O'Connor L, Murata-Kamiya N, Hatakeyama M, Judd LM, Giraud AS, Menheniott TR. Helicobacter pylori CagA triggers expression of the bactericidal lectin REG3gamma via gastric STAT3 activation. PLoS ONE. 2012; 7(2): e30786
Howlett M, Chalinor HV, Buzzelli JN, Nguyen N, van Driel IR, Bell KM, Fox JG, Dimitriadis E, Menheniott TR, Giraud AS, Judd LM. IL-11 is a parietal cell cytokine that induces atrophic gastritis. Gut. 2012; 61(10): 1398-409
Tomita H, Takaishi S, Menheniott TR, Yang X, Shibata W, Jin G, Betz KS, Kawakami K, Minamoto T, Tomasetto C, Rio MC, Lerkowit N, Varro A, Giraud AS, Wang TC. Inhibition of gastric carcinogenesis by the hormone, gastrin, is mediated by suppression of TFF1 epigenetic silencing. Gastroenterology. 2011; 140(3): 879-91
Menheniott TR*, Peterson AJ*, O'Connor L, Walduck AK, Fox JG, Kawakami K, Minamoto T, Ong EK, Wang TC, Judd LM, Giraud AS. Helicobacter pylori infection promotes methylation and silencing of Trefoil factor 2 leading to gastric tumor development in mice and humans. Gastroenterology. 2010; 139(6): 2005-17. *Equal first authors
Menheniott TR, Peterson AJ, O'Connor L, Lee KS, Kalantzis A, Kondova I, Bontrop RE, Bell KM, Giraud AS. A novel Gastrokine, Gkn3, marks gastric atrophy and shows evidence of adaptive gene loss in humans. Gastroenterology. 2010; 138(5): 1823-35
Menheniott TR, Woodfine K, Schulz R, Wood AJ, Monk D, Giraud AS, Baldwin HS, Moore GE, Oakey RJ. Genomic imprinting of dopa decarboxylase in heart and reciprocal allelic expression with neighbouring Grb10. Mol Cell Biol. 2008; 28(1): 386-96